REGULATORY INTELLIGENCE·Recall
Vilvet Pharmaceuticals' VILEVEV MB Recall Highlights Persistent cGMP Compliance Risks for Urinary Antiseptics
Vilvet Pharmaceuticals Inc. initiated a Class II nationwide recall of 1,716 bottles of VILEVEV MB Urinary Antispetic due to cGMP deviations. This event, terminated in January 2022, underscores persistent quality control challenges in pharmaceutical manufacturing. Procurement and regulatory teams must enhance supplier due diligence and quality oversight to mitigate supply chain disruptions and ensure patient safety from similar compliance risks.
90-Day Activity